RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.48
−4.40%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +47.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +100.0%
- EPS
- +86.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +33.6%
- EBIT
- +34.4%
- Net income
- +33.6%
- EPS
- +69.6%
- Free cash flow
- +26.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026